Medical Education Grants: Fibrosing Interstitial Lung Disease (ILDs)
Independent Medical Education (IME) Grants
Boehringer Ingelheim is proud to provide Independent Medical Education (IME) Grant support for evidence-based, fair-balanced, unbiased healthcare professional (HCP) education to help close clinical and practice gaps, improve the quality and delivery of patient care, and enhance behavioral change.
An independent educational program includes both continuing medical education (CME) and non-CME programs. These programs may be at the national, regional, or local level and may include didactic presentations (eg, symposia at educational meetings, grand rounds, and regional workshops), web-based programs, print and electronic monographs, and innovative educational formats.
-
Pathophysiology, Prevalence, Burden of Disease
-
Increase the healthcare team’s understanding of the pathophysiology, prevalence, morbidity and mortality, burden of disease, mental health impacts, and signs and symptoms of fibrosing ILDs (i.e., IPF, PPF, SARD-ILD)
- Increase understanding of the various mechanisms and patterns of cough in fibrosing ILDs, including triggers, characteristics, and impact on quality of life
Diagnosis
-
Increase the healthcare team’s awareness of fibrosing ILDs (i.e., IPF, PPF, SARD-ILD) to encourage earlier diagnosis and referral to appropriate specialists or specialty centers
- Improve the healthcare team’s knowledge of updated diagnostic guidelines and recommended testing methods, such as high resolution computed tomography, and interpretation
- Increase awareness of the importance of routine assessments in patients with fibrosing ILDs (i.e., IPF, PPF, SARD-ILD) to promptly identify lung involvement, acute exacerbations, and disease progression
-
Increase understanding of the significance, interpretation, and management approaches for interstitial lung abnormalities (ILAs) identified on radiological imaging, including appropriate follow-up strategies and risk assessment
Clinical Management
-
Improve the healthcare team’s knowledge regarding future horizons in diagnosis, follow up, screening, management, and treatment of fibrosing ILDs (i.e., IPF, PPF, SARD-ILD) including developments in clinical research, treatment guidelines, and emerging therapies
-
Increase the healthcare team’s knowledge of oxygen requirements, prescription patterns, and the physical, social, and emotional burden of oxygen therapy in patients with pulmonary fibrosis
-
Improve multidisciplinary management of the possible fibrosing ILD (i.e., IPF, PPF, SARD-ILD) risk factors and comorbidities
-
Improve effective communication with, and education of, fibrosing ILD patients and their caregivers about their disease
-
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.